NxStage Medical Inc. (NASDAQ:NXTM) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.58 and last traded at $25.52, with a volume of 456,789 shares traded. The stock had previously closed at $25.16.

NXTM has been the subject of several research reports. BTIG Research restated a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research report on Tuesday, June 7th. Northland Securities upgraded NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 28th. Piper Jaffray Cos. restated an “overweight” rating and set a $21.00 price objective on shares of NxStage Medical in a research report on Tuesday, May 17th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Wednesday, July 6th. Finally, Jefferies Group lifted their price objective on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $26.43.

The company has a 50 day moving average price of $22.29 and a 200-day moving average price of $18.17. The stock’s market capitalization is $1.66 billion.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company earned $92.20 million during the quarter, compared to the consensus estimate of $89.44 million. The company’s revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.08) earnings per share. Analysts predict that NxStage Medical Inc. will post ($0.12) earnings per share for the current year.

Several hedge funds and institutional investors recently bought and sold shares of the stock. Trexquant Investment LP boosted its position in NxStage Medical by 142.4% in the fourth quarter. Trexquant Investment LP now owns 57,700 shares of the medical device company’s stock valued at $1,264,000 after buying an additional 33,900 shares during the period. Morgan Stanley boosted its position in NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock valued at $1,472,000 after buying an additional 874 shares during the period. Rhumbline Advisers boosted its position in NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock valued at $1,499,000 after buying an additional 5,240 shares during the period. New York State Common Retirement Fund boosted its position in NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock valued at $1,676,000 after buying an additional 3,000 shares during the period. Finally, Jennison Associates LLC boosted its position in NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock valued at $30,568,000 after buying an additional 345,394 shares during the period.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.